Business Context and Reporting Period
Company: PharmAthene, Inc. (Note: Input metadata referenced Altimmune, Inc., but the filing text identifies PharmAthene, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2009
Business Overview: PharmAthene is a biodefense company developing medical countermeasures against biological and chemical weapons. Key product candidates include SparVax (anthrax vaccine), Valortim (anthrax anti-toxin), Protexia (nerve agent protectant), and RypVax (plague vaccine). The company relies heavily on U.S. government contracts for funding and has no commercial products currently generating revenue.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2009 | Nine Months Ended Sep 30, 2009 | Dec 31, 2008 (Balance Sheet) |
|---|---|---|---|
| Total Revenue | $6.83 million | $20.42 million | N/A |
| Net Loss | $(13.96) million | $(26.61) million | N/A |
| Loss Per Share (Basic/Diluted) | $(0.50) | $(0.97) | N/A |
| Cash and Cash Equivalents | $4.19 million | N/A | $19.75 million |
| Total Assets | N/A | N/A | $41.97 million |
| Total Liabilities | N/A | N/A | $35.48 million |
| Stockholders' Equity | N/A | N/A | $6.49 million |
| Accumulated Deficit | N/A | N/A | $(150.64) million |
Cash Flow (Nine Months Ended Sep 30, 2009):
- Net cash used in operating activities: $(21.96) million
- Net cash used in investing activities: $(12.74) million
- Net cash provided by financing activities: $18.64 million
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 36% in the three months ended Sep 30, 2009, compared to the same period in 2008 ($6.83M vs. $10.68M). This was primarily due to the completion of the initial phase of the Protexia contract with the DoD and a slowdown in SparVax development activities during the technology transfer from the UK to the US.
- Net Loss Increase: Net loss increased significantly in the three-month period ($13.96M vs. $4.34M in 2008) and decreased slightly in the nine-month period ($26.61M vs. $31.21M in 2008). The Q3 increase was driven by a $4.69 million loss on the early extinguishment of debt and a $1.06 million loss on the change in fair value of derivative instruments.
- Debt Restructuring: In July 2009, the company exchanged $8.8 million of "Old Notes" and issued $10.5 million in new convertible notes ("New Convertible Notes"). This resulted in a $4.69 million loss on extinguishment of debt.
- Liquidity Position: Cash and cash equivalents dropped from $19.75 million at year-end 2008 to $4.19 million at Sep 30, 2009. However, restricted cash of $13.25 million was released following the settlement of the Avecia Acquisition deferred consideration.
Guidance, Outlook, Risks, and Unusual Items
- Clinical Hold: In August 2009, the FDA placed a partial clinical hold on the Phase I trial of Valortim (anthrax anti-toxin) following two adverse reactions in subjects. BARDA has paused negotiations for additional funding until the hold is lifted.
- Contract Wind-Downs: The company and the U.S. government agreed to reduce the scope of work for the RypVax (plague vaccine) program, with activities expected to wind down by the end of the first half of 2010. The Protexia contract with the DoD is also expected to conclude its initial phase, with a funding decision for the next phase anticipated in Q1 2010.
- Going Concern: Management believes current cash resources and contract receivables will fund operations through the end of 2010. However, the company has a history of losses and negative cash flow, and future profitability is uncertain.
- Legal Proceedings: The company is involved in litigation with Siga Technologies, Inc., regarding rights to the drug candidate SIGA-246. Trial is expected in 2010.
- Unusual Items: The $4.69 million loss on debt extinguishment and the $1.06 million loss on derivative instruments were significant non-operating expenses in Q3 2009.
Investor Verification Checklist
- Cash Runway: Verify if the $4.19 million in cash plus unbilled receivables is sufficient to fund operations through 2010 without additional dilutive financing.
- Valortim Clinical Hold: Monitor the resolution of the FDA clinical hold on Valortim, as this directly impacts potential BARDA funding and the product's development timeline.
- Government Contract Awards: Track the status of the RFP-BARDA-08-15 for the SparVax anthrax vaccine, a critical potential revenue source that has faced multiple delays.
- Debt Covenants: Review the terms of the July 2009 New Convertible Notes, specifically the requirement to register shares by November 25, 2009, to avoid penalty payments.
- UK to US Transition: Assess the progress and costs associated with transferring manufacturing and operations from the UK to the US, including the termination of the UK workforce by June 30, 2010.